Not recruiting
Hodgkin's disease refractory+1
Not recruitingStudy of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Registered drugNo placebo
Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Registered drugNo placebo
- Disease:Hodgkin's disease refractoryPrimary mediastinal large B-cell lymphoma refractory
- Substances:Pembrolizumab
Countries:
Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Merck Sharp & Dohme LLC


